Efficacy And Safety Of Poziotinib In Treatment-Naive Nsclc Harboring Her2 Exon 20 Mutations: A Multinational Phase Ii Study (Zenith20-4)

Treatment of non-small cell lung cancer (NSCLC) with EGFR and HER2 exon 20 mutations is an unmet medical need. We evaluated the efficacy and safety of poziotinib, a potent tyrosine kinase inhibitor (TKI) able to overcome the restricted binding pocket of exon 20 mutations, in newly diagnosed patients with NSCLC and HER2 exon 20 insertion mutations in a multinational, multi-cohort Phase 2 study.